Mark Raffeld

机构：National Institutes of Health, National Cancer Institute, Center for Cancer Research · ORCID：0000-0002-4039-6957

发表论文 795 篇 · 总被引 46271 次 · h-index 113

代表论文

• Multigenerational VHL family characterized by pathogenic germline ELOC variant: Response to belzutifan (2025 · Urologic Oncology Seminars and Original Investigations · 被引 4)
• Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases (2026 · Neuro-Oncology · 被引 3)
• Tuberous sclerosis complex-associated renal cell carcinoma, an underappreciated form of familial renal cancer, is characterized by activation of the TFEB/TFE3 pathway (2025 · Human Molecular Genetics · 被引 2)
• Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia (2025 · Blood · 被引 2)
• DNA methylation-based classification of hematolymphoid neoplasms (2026 · Blood Advances · 被引 1)
• Enitociclib ( VIP152 ), venetoclax and prednisone in relapsed or refractory aggressive non‐Hodgkin lymphoma (2025 · British Journal of Haematology · 被引 1)